A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis.
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2013
At a glance
- Drugs Ceralifimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Acronyms DreaMS
- Sponsors Ono Pharmaceutical
- 23 Mar 2013 Results using the more sensitive statistical method presented at the 65th Annual Meeting of the American Academy of Neurology.
- 07 Dec 2012 Last checked against ClinicalTrials.gov record (Parent Trial; NCT01081782).
- 13 Oct 2012 Results presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History